Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVI.ad

Imaging: Lung cysts or bullae (see also XVI ah/bf)

Publications

Souza FF, Smith A, Araujo C, Jagannathan J, Johnston C, O'Regan K, Shinagare A, Ramaiya N

New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know.

Cancer imaging : the official publication of the International Cancer Imaging Society 2014 Jul 23;14;26 — 2014 Jul 23 — 26

Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.

Cancer imaging : the official publication of the International Cancer Imaging Society 2012 Jun 29;12;225-35 — 2012 Jun 29 — 225-35

Kelly RJ, Hnatiuk O, Giaccone G

Antiangiogenesis induced tumor cavitation in lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009 Dec;4;1573-5 — 2009 Dec — 1573-5